AI Image
New weight-loss drug targets belly fat and can give 'flatter stomach' in weeks
New York Post • • health
Key Points:
- CBL-514 is a new injectable drug that targets fat cells by causing them to self-destruct at the injection site, reducing both subcutaneous and visceral fat without invasive surgery.
- Phase 2 clinical trials showed that CBL-514 reduced visceral abdominal fat by 12% after four weeks and maintained a 10.45% reduction after eight weeks, with early data suggesting lasting effects on fat loss.
- Unlike GLP-1 drugs, which reduce appetite but also cause loss of lean mass and weight regain after stopping, CBL-514 may offer a more fundamental obesity treatment by directly eliminating fat cells and potentially preventing regrowth.
- The drug was generally well tolerated with only mild-to-moderate injection site reactions reported, and it is now entering Phase 3 trials ahead of potential FDA approval.
- Researchers are investigating whether CBL-514 can be combined with GLP-1 drugs to enhance weight loss maintenance and reduce the risk of weight regain after stopping medication.
